StockData

Cue Biopharma vs vTv Therapeutics

CUE and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CUE and VTVT compare

vTv Therapeutics is the larger company, worth 3.3 times as much as Cue Biopharma ($68.4M against $20.6M).

vTv Therapeutics grew revenue faster over the last twelve months (216600% versus 354% for Cue Biopharma).

vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −436% at Cue Biopharma.

vTv Therapeutics scores higher on the StockData Score (11 against 8 for Cue Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCUEVTVT
Size and price
Market cap$20.6M$68.4M
Share price$2.83$17.29
Change, 1 year−85.0%−43.9%
Change, 5 years−99.3%−67.7%
Beta (5Y)–0.08
Employees2926
StockData Score
Total score811 (better)
Valuation score03 (better)
Growth score2 (better)1
Performance score12 (better)
Health score55
Dividend score00
Valuation
P/S0.5× (better)1.9×
P/B8.9×0.9× (better)
FCF yield−244%–
Fair value–$44.97
Margin of safety–61.6%
Growth
Revenue growth (TTM)354%216600% (better)
Revenue growth, 5Y average54.2%–
Profitability
Operating margin−262%−25.1% (better)
Net margin−436%−12.9% (better)
FCF margin−133%–
Return on equity−1603%−11.7% (better)
Financial health
Debt / equity0.000.00
Current ratio1.2512.48 (better)
Altman Z-score−32.750.71 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions22.6%40.6%
Held by insiders17.4%26.3%
Insider net buying, 12 months−$2.3M–
Short interest, % of float14.4%5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.